(TVTX) Travere Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.808m USD | Total Return: 100.7% in 12m

Sparsentan, Tiopronin, Filspari, Thiola
Total Rating 48
Safety 28
Buy Signal -0.81
Biotechnology
Industry Rotation: +3.6
Market Cap: 2.81B
Avg Turnover: 29.6M USD
ATR: 4.67%
Peers RS (IBD): 51.7
Risk 5d forecast
Volatility65.0%
Rel. Tail Risk-10.8%
Reward TTM
Sharpe Ratio1.06
Alpha43.55
Character TTM
Beta1.910
Beta Downside2.872
Drawdowns 3y
Max DD76.74%
CAGR/Max DD0.18
EPS (Earnings per Share) EPS (Earnings per Share) of TVTX over the last years for every Quarter: "2021-03": -0.96, "2021-06": -0.64, "2021-09": -0.59, "2021-12": -0.84, "2022-03": -1.2, "2022-06": -1.05, "2022-09": -1.09, "2022-12": -1.03, "2023-03": -1.27, "2023-06": -1.13, "2023-09": -1.17, "2023-12": -1.18, "2024-03": -1.76, "2024-06": -0.91, "2024-09": -0.7, "2024-12": -0.47, "2025-03": -0.19, "2025-06": 0.13, "2025-09": 0.59, "2025-12": 0.37, "2026-03": 0,
EPS CAGR: 24.89%
EPS Trend: 82.4%
Last SUE: 0.20
Qual. Beats: 0
Revenue Revenue of TVTX over the last years for every Quarter: 2021-03: 47.407, 2021-06: 54.617, 2021-09: 68.217, 2021-12: 57.249, 2022-03: 48.487, 2022-06: 54.167, 2022-09: 28.075, 2022-12: 55.868, 2023-03: 56.993, 2023-06: 32.196, 2023-09: 37.095, 2023-12: 45.059, 2024-03: 41.374, 2024-06: 54.116, 2024-09: 62.898, 2024-12: 74.787, 2025-03: 81.732, 2025-06: 114.449, 2025-09: 164.859, 2025-12: 129.689, 2026-03: null,
Rev. CAGR: 30.00%
Rev. Trend: 76.0%
Last SUE: -0.60
Qual. Beats: 0
Warnings

High Debt/EBITDA (11.1) with thin interest coverage (-3.6)

Interest Coverage Ratio -3.6 is critical

Altman Z'' -8.51 < 1.0 - financial distress zone

volatile

Tailwinds

No distinct edge detected

Description: TVTX Travere Therapeutics

Travere Therapeutics (NASDAQ: TVTX) is a U.S. biotech focused on rare kidney and metabolic disorders, commercializing FILSPARI (sparsentan) for IgA Nephropathy and Thiola/Thiola EC for cystinuria, while advancing orphan-designated programs such as sparsentan for focal segmental glomerulosclerosis and peg-tibatinase for classical homocystinuria.

As of the latest quarter (Q4 2025), Travere reported $45 million in total revenue, a cash runway of roughly $410 million, and an R&D spend of $115 million, reflecting its heavy pipeline investment. The Phase 3 PROTECT trial for sparsentan in IgA Nephropathy met its primary endpoint in January 2025, positioning the drug for a potential FDA submission later this year. The broader biotech sector continues to benefit from heightened investor appetite for orphan-drug pipelines, with the U.S. rare-disease market projected to grow at a CAGR of 9% through 2030.

For a deeper dive into valuation nuances, you might explore ValueRay’s analyst commentary.

Headlines to Watch Out For
  • FILSPARI sales growth drives revenue
  • Thiola franchise sales contribute steady revenue
  • Sparsentan regulatory approval for FSGS expands market
  • Pegtibatinase clinical trial results impact future pipeline
  • Competition from new rare disease therapies poses risk
Piotroski VR‑10 (Strict) 5.0
Net Income: -50.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA 50.36 > 1.0
NWC/Revenue: 56.58% < 20% (prev 92.61%; Δ -36.03% < -1%)
CFO/TA 0.06 > 3% & CFO 37.8m > Net Income -50.3m
Net Debt (246.8m) to EBITDA (22.2m): 11.11 < 3
Current Ratio: 2.74 > 1.5 & < 3
Outstanding Shares: last quarter (90.3m) vs 12m ago 8.65% < -2%
Gross Margin: 94.20% > 18% (prev 0.92%; Δ 9.33k% > 0.5%)
Asset Turnover: 81.83% > 50% (prev 39.25%; Δ 42.59% > 0%)
Interest Coverage Ratio: -3.58 > 6 (EBITDA TTM 22.2m / Interest Expense TTM 10.8m)
Altman Z'' -8.51
A: 0.46 (Total Current Assets 437.6m - Total Current Liabilities 159.9m) / Total Assets 605.2m
B: -2.43 (Retained Earnings -1.47b / Total Assets 605.2m)
C: -0.06 (EBIT TTM -38.5m / Avg Total Assets 599.7m)
D: -3.01 (Book Value of Equity -1.47b / Total Liabilities 490.4m)
Altman-Z'' Score: -8.51 = D
Beneish M -2.08
DSRI: 1.43 (Receivables 81.4m/27.1m, Revenue 490.7m/233.2m)
GMI: 0.98 (GM 94.20% / 92.24%)
AQI: 0.95 (AQ_t 0.25 / AQ_t-1 0.27)
SGI: 2.10 (Revenue 490.7m / 233.2m)
TATA: -0.15 (NI -50.3m - CFO 37.8m) / TA 605.2m)
Beneish M-Score: -2.08 (Cap -4..+1) = BB
What is the price of TVTX shares? As of April 07, 2026, the stock is trading at USD 30.44 with a total of 1,149,800 shares traded.
Over the past week, the price has changed by +10.05%, over one month by +11.46%, over three months by -20.13% and over the past year by +100.66%.
Is TVTX a buy, sell or hold? Travere Therapeutics has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy TVTX.
  • StrongBuy: 11
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the TVTX price?
Analysts Target Price 42.5 39.6%
Travere Therapeutics (TVTX) - Fundamental Data Overview as of 04 April 2026
P/E Forward = 48.0769
P/S = 5.7218
P/B = 25.2397
Revenue TTM = 490.7m USD
EBIT TTM = -38.5m USD
EBITDA TTM = 22.2m USD
Long Term Debt = 311.7m USD (from longTermDebt, last quarter)
Short Term Debt = 5.88m USD (from shortTermDebt, last quarter)
Debt = 339.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 246.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.82b USD (2.81b + Debt 339.9m - CCE 322.8m)
Interest Coverage Ratio = -3.58 (Ebit TTM -38.5m / Interest Expense TTM 10.8m)
EV/FCF = 108.7x (Enterprise Value 2.82b / FCF TTM 26.0m)
FCF Yield = 0.92% (FCF TTM 26.0m / Enterprise Value 2.82b)
FCF Margin = 5.30% (FCF TTM 26.0m / Revenue TTM 490.7m)
Net Margin = -10.24% (Net Income TTM -50.3m / Revenue TTM 490.7m)
Gross Margin = 94.20% ((Revenue TTM 490.7m - Cost of Revenue TTM 28.5m) / Revenue TTM)
Gross Margin QoQ = 84.05% (prev none%)
Tobins Q-Ratio = 4.67 (Enterprise Value 2.82b / Total Assets 605.2m)
Interest Expense / Debt = 0.68% (Interest Expense 2.30m / Debt 339.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -30.4m (EBIT -38.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.74 (Total Current Assets 437.6m / Total Current Liabilities 159.9m)
Debt / Equity = 2.96 (Debt 339.9m / totalStockholderEquity, last quarter 114.8m)
Debt / EBITDA = 11.11 (Net Debt 246.8m / EBITDA 22.2m)
Debt / FCF = 9.49 (Net Debt 246.8m / FCF TTM 26.0m)
Total Stockholder Equity = 63.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.38% (Net Income -50.3m / Total Assets 605.2m)
RoE = -79.16% (Net Income TTM -50.3m / Total Stockholder Equity 63.5m)
RoCE = -10.27% (EBIT -38.5m / Capital Employed (Equity 63.5m + L.T.Debt 311.7m))
 RoIC = -7.44% (negative operating profit) (NOPAT -30.4m / Invested Capital 409.1m)
 WACC = 11.39% (E(2.81b)/V(3.15b) * Re(12.70%) + D(339.9m)/V(3.15b) * Rd(0.68%) * (1-Tc(0.21)))
Discount Rate = 12.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.66%
[DCF] Terminal Value 68.39% ; FCFF base≈26.0m ; Y1≈27.9m ; Y5≈34.1m
[DCF] Fair Price = 1.20 (EV 357.4m - Net Debt 246.8m = Equity 110.6m / Shares 92.2m; r=11.39% [WACC]; 5y FCF grow 8.24% → 3.0% )
EPS Correlation: 82.35 | EPS CAGR: 24.89% | SUE: 0.20 | # QB: 0
Revenue Correlation: 76.04 | Revenue CAGR: 30.00% | SUE: -0.60 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.34 | Chg7d=-0.011 | Chg30d=+0.079 | Revisions Net=+0 | Analysts=7
EPS current Year (2026-12-31): EPS=1.59 | Chg7d=-0.350 | Chg30d=-0.166 | Revisions Net=-2 | Growth EPS=+74.4% | Growth Revenue=+42.7%
EPS next Year (2027-12-31): EPS=4.26 | Chg7d=+0.833 | Chg30d=+0.937 | Revisions Net=+2 | Growth EPS=+168.5% | Growth Revenue=+32.4%
[Analyst] Revisions Ratio: +0.00 (2 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle